- Associated Press•4 hours ago
U.S. regulators on Tuesday approved the first lower-cost version of Enbrel, a blockbuster anti-inflammatory drug from Amgen that is among the top-selling drugs in the world.
- Reuters•5 hours ago
The U.S. Food and Drug Administration on Tuesday approved Novartis AG's biosimilar version of Amgen Inc's arthritis drug Enbrel. The FDA approved the drug, Erelzi, known also as etanercept-szzs, for multiple inflammatory conditions including rheumatoid arthritis and plaque psoriasis, a skin condition. The agency approved the drug as a biosimilar, meaning there is no clinically meaningful differences between Erelzi and Enbrel.
- Insider Monkey•yesterday
Novartis AG (ADR) (NYSE:NVS) just put out data from its multiple sclerosis (MS) trial, and it looks as if the company is winning the race to bring a drug to market that offers a solution for patients with secondary progressive MS (SPMS), a severe form of the condition. Biogen Inc (NASDAQ:BIIB) is also working on […]
Novartis AG (NVS)
NYSE - NYSE Real Time Price. Currency in USD
|Day's Range||79.28 - 79.65|
|52wk Range||69.90 - 98.95|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||28.33|
|Avg Vol (3m)||1,467,157|
|Dividend & Yield||2.72 (3.43%)|